ArticleCancer management and research2018
Distinct prognostic value of dynactin subunit 4 (DCTN4) and diagnostic value of DCTN1, DCTN2, and DCTN4 in colon adenocarcinoma.
Article in Cancer management and research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 25 citations in OpenAlex.
- Case Report: imaging features of anaplastic lymphoma kinase-rearranged renal cell carcinoma with a novelFrontiers in oncology · 2026Article
- Altered expression of vesicular trafficking machinery in prostate cancer affects lysosomal dynamics and provides insight into the underlying biology and disease progression.British journal of cancer · 2024Article
- LINC01094: A key long non-coding RNA in the regulation of cancer progression and therapeutic targets.Heliyon · 2024Review
- Pan-cancer analysis of DCTN2 and its tumour-promoting role in HCC by modulating the AKT pathway.Journal of cellular and molecular medicine · 2024Article
- Comprehensive analysis indicated that NDE1 is a potential biomarker for pan-cancer and promotes bladder cancer progression.Cancer medicine · 2024Article
- Article
- Mechanistic Insights into the Anti-Proliferative Action of Gut Microbial Metabolites against Breast Adenocarcinoma Cells.International journal of molecular sciences · 2023Article
- Dynactin 2 acts as an oncogene in hepatocellular carcinoma through promoting cell cycle progression.Liver research (Beijing, China) · 2022Article
- The regulatory landscape of retinoblastoma: a pathway analysis perspective.Royal Society open science · 2022Article
- Glycosylation-Related Genes Predict the Prognosis and Immune Fraction of Ovarian Cancer Patients Based on Weighted Gene Coexpression Network Analysis (WGCNA) and Machine Learning.Oxidative medicine and cellular longevity · 2022Article
- Identification of DNA Repair-Related Genes Predicting Clinical Outcome for Thyroid Cancer.Journal of oncology · 2022Article
- Binding between ROCK1 and DCTN2 triggers diabetes‑associated centrosome amplification in colon cancer cells.Oncology reports · 2021Article
- Construction and Identification of a Novel 5-Gene Signature for Predicting the Prognosis in Breast Cancer.Frontiers in medicine · 2021Article
- Down-regulated Solute Carrier Family 4 Member 4 Predicts Poor Progression in Colorectal Cancer.Journal of Cancer · 2020Article
- Linc01094 Accelerates the Growth and Metastatic-Related Traits of Glioblastoma by Sponging miR-126-5p.OncoTargets and therapy · 2020Article
- The YTH Domain Family of N6-Methyladenosine "Readers" in the Diagnosis and Prognosis of Colonic Adenocarcinoma.BioMed research international · 2020Article
- Identification of a novel glycolysis-related gene signature for predicting metastasis and survival in patients with lung adenocarcinoma.Journal of translational medicine · 2019Article
- Study on the Prognostic Values of Dynactin Genes in Low-Grade Glioma.Technology in cancer research & treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColon adenocarcinoma (COAD) is ranked as the third most commonly diagnosed cancer in both women and men, and it is the most frequently occurring malignant tumor. Dynactin is a protein compound based on multiple subunits, including dynactin 1-6 (DCTN1-6), in most categories of cytoplasmic dynein performance in eukaryotes. Nevertheless, correlations between the DCTN family and the prognosis and diagnosis of COAD remain unidentified.
methodsStatistics for DCTN mRNA expression in patients with COAD were acquired from The Cancer Genome Atlas. Kaplan-Meier analyses and a Cox regression model were applied to determine overall survival, with computation of HRs and 95% CIs. Several online data portals were used to assess the biological process, and pathway examination was performed using the Kyoto Encyclopedia of Genes and Genomes to predict the biological functionality of
resultsWe found that high expression of DCTN4 was linked with satisfactory results for overall survival (
conclusionThe expression levels of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.